Attività Prestazioni Didattica Corsi Eventi Bandi Contatti
Istituto > Pubblicazioni > Anno 2008
Pubblicazioni Istituto inserite in PubMed e nell'Osservatorio della Ricerca - Anno 2008

Finelli C, Terenzi A, Poloni A. Trapianto di Cellule Staminali. In Sindromi Mielodisplastiche. Dalla teoria alla pratica clilnica. Elsevier Masson, 2008.

Finelli C, Bosi C, Clissa C. Supporto trasfusionale e chelazione. In Sindromi Mielodisplastiche.Dalla teoria alla pratica clinica. Elsevier Masson, 2008.

Palandri F, Iacobucci I, Martinelli G, Amabile M,Poerio A, Testoni N,Soverini S, Castagnetti F, De Vivo A, Breccia M, SpecchiaG, Abruzzese E,  Martino B, Cilloni D, Saglio G, Pane F, Liberati AM, Rosti G,Baccarani M; GIMEMA Working Party on CML  Long-term outcome of completecytogenetic responders after imatinib 400 mg in late chronic phase,philadelphia-positive chronic myeloid  leukemia: the GIMEMA Working Party onCML J Clin Oncol. 2008 Jan 1;26(1):106-11.

Derenzini E, Paolini S, Martinelli G, Campidelli C,Grazi GL, Calabrese C,Zinzani PL, Baccarani M  Extramedullary myeloid tumour of thestomach and duodenum presenting without acute myeloblastic leukemia: adiagnostic and  therapeutic challenge Leuk Lymphoma. 2008 Jan;49(1):159-62.

Papa V, Tazzari PL, Chiarini F, Cappellini A, Ricci F,Billi AM, Evangelisti  C, Ottaviani E, Martinelli G, Testoni N, McCubrey JA,Martelli AM  Proapoptotic activity andchemosensitizing effect of the novel Akt inhibitor perifosine in acutemyelogenous leukemia cells Leukemia. 2008 Jan;22(1):147-60.

Follo MY, Finelli C, Bosi C, Martinelli G, Mongiorgi S,Baccarani M, Manzoli  L, Blalock WL, Martelli AM, Cocco L  PI-PLCbeta-1 and activated Akt levelsare linked to azacitidine responsiveness in high-risk myelodysplasticsyndromes Leukemia. 2008 Jan;22(1):198-200.

Tosi P, Terragna C, Testoni N, Zamagni E, Renzulli M,Tacchetti P, Montanari  E, Perrone G, Ceccolini M, Brioli A, Pallotti MC,Tura S,  Baccarani M, Cavo M  Evaluation of bone disease inmultiple myeloma patients carrying the t(4;14) chromosomal translocation Eur J Haematol. 2008 Jan;80(1):31-6.

Zinzani PL,d'Amore F, Bombardieri E, Brammer C, Codina JG, Illidge T,Jurczak W, LinkeschW, Morschhauser F, Vandenberghe E, Van  Hoof A  Consensus conference: implementingtreatment recommendations on yttrium-90 immunotherapy in clinical practice -report of a European  workshop Eur J Cancer. 2008 Feb;44(3):366-73.

Bocchia M, Ippoliti M, Gozzetti A, Abruzzese E,Calabrese S, Amabile M,Pirrotta MT, Crupi R, Tozzuoli D, Trawinska MM, DefinaM, Martinelli G,  Lauria F  CD34+/Ph+ cells are still detectablein chronic myeloid leukemia patients with sustained and prolonged completecytogenetic remission during treatment with imatinib mesylate Leukemia. 2008 Feb;22(2):426-8.

Palumbo A, Rajkumar SV, Dimopoulos MA,Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M,Zangari M, Attal M,  Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D,Bladé J, Kyle R, Westin J, Weber D, Bringhen S,Niesvizky R, Waage A,  Prevention of thalidomide- andlenalidomide-associated thrombosis in myeloma Leukemia. 2008 Feb;22(2):414-23. Epub2007 Dec 20. Review.

Zinzani PL, Ferreri AJ, Cerroni L  Mycosis fungoides Crit Rev Oncol Hematol. 2008Feb;65(2):172-82.

Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G,Vitolo U, Perrotti A,Fina M, Derenzini E, Baccarani M  A phase 2 trial of fludarabine andmitoxantrone chemotherapy followed by yttrium-90 ibritumomab tiuxetan forpatients with previously  untreated, indolent,nonfollicular, non-Hodgkinlymphoma Cancer. 2008 Feb 15;112(4):856-62.

Baccarani M, Pane F, Saglio G  Monitoring treatment of chronicmyeloid leukemia Haematologica. 2008 Feb;93(2):161-9.Review.

Giles FJ, DeAngelo DJ, Baccarani M,Deininger M, Guilhot F, Hughes T, Mauro M,Radich J, Ottmann O, Cortes J  Optimizing outcomes for patients withadvanced disease in chronic myelogenous leukemia Semin Oncol. 2008 Feb;35(1 Suppl1):S1-17; quiz S18-20. Review.

Palmisano M, Grafone T, Renzulli M, Ottaviani E,Testoni N, Paolini S,Papayannidis C, Baccarani M, Martinelli G  Molecular and chromosomalalterations: new therapies for relapsed acute myeloid leukemia Hematology. 2008 Feb;13(1):1-12.Review.

le Coutre P, Ottmann OG, Giles F, KimDW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG,Kuliczkowski K,  Hochhaus A, Mahon FX,Saglio G, Gobbi M, Kwong YL, BaccaraniM, Hughes T, Martinelli G, Radich JP,Zheng M, Shou Y, Kantarjian H  Nilotinib (formerly AMN107), a highlyselective BCR-ABL tyrosine kinase inhibitor, is active in patients withimatinib-resistant or -intolerant  accelerated-phase chronic myelogenousleukemia Blood. 2008 Feb 15;111(4):1834-9.

Radi M, Crespan E, Botta G, Falchi F, Maga G, Manetti F, Corradi V, Mancini M, Santucci MA, Schenone S, Botta M. Discovery and SAR of 1,3,4-thiadiazole derivatives as potent Abl tyrosine kinase inhibitors and cytodifferentiating agents.Bioorg Med Chem Lett 2008 Feb 1;18(3):1207-11.

Chunduri S, Mahmud D, Abbasian J, Arpinati M, RondelliD  Cord blood nucleated cells inducedelayed T cell alloreactivity Biol Blood Marrow Transplant. 2008 Aug;14(8):872-9.

Grafone T, Palmisano M, Nicci C, Martelli AM, EmanuelaO, Storti S, Baccarani M, Martinelli G  Monitoring of FLT3 phosphorylationstatus and its response to drugs by flow cytometry in AML blast cells Hematol Oncol. 2008 Mar31;26(3):159-166.

Rothenberg ME, Klion AD, Roufosse FE,Kahn JE, Weller PF, Simon HU, Schwartz  LB, Rosenwasser LJ, Ring J, GriffinEF, Haig AE, Frewer  PI, Parkin JM, Gleich GJ; Mepolizumab HES Study Group  Treatment of patients with thehypereosinophilic syndrome with mepolizumab N Engl J Med. 2008 Mar 20;358(12):1215-28.

Ambrosini V, Quarta C, Zinzani PL, Fini M, Giavaresi G,Torricelli P, Malvi D,Nanni C, Grassetto G, Rubello D, Fanti S  18F-FDG small animal PET for earlydetection of human anaplastic large cells lymphoma xenograft inimmunocompromised mice Anticancer Res. 2008 Mar-Apr;28(2A):981-7. 

Mancini M, Zuffa E, Veljkovic N, Brusa G, Corrado P,Corradi V, Martinelli G,Barbieri E, Santucci MA  IPO-trimethylation of histoneH3-lysine9 associated with P210 BCR-ABL tyrosine kinase of chronic myeloidleukaemia Br J Haematol. 2008Jun;141(6):899-902. Epub 2008 Mar 27.

Rapezzi C, Riva L, Quarta CC, Perugini E, Salvi F,Longhi S, Ciliberti P,Pastorelli F, Biagini E, Leone O, Cooke RM,Bacchi-Reggiani L,  Ferlini A, Cavo M,Merlini G, Perlini S, Pasquali S, BranziA  Gender-related risk of myocardialinvolvement in systemic amyloidosis Amyloid. 2008 Mar;15(1):40-8.

Arpinati M, Chirumbolo G, Nicolini B, Agostinelli C,Rondelli D  Selective apoptosis of monocytes andmonocyte-derived DCs induced by Bortezomib (Velcade) Bone Marrow Transplant. 2008 Sep 22.

Curti A, Trabanelli S, Lemoli RM More ADO about IDO: GvHD Blood 2008 Mar 15;111(6):2950  26 Lemoli RM, D'Addio A  Hematopoietic stem cell mobilization Haematologica. 2008 Mar;93(3):321-4.

De Stefano V, Za T, Rossi E, VannucchiAM, Ruggeri M, Elli E, Micò C, Tieghi A, Cacciola RR, Santoro C, Gerli G,Vianelli N, Guglielmelli P,  Pieri L,Scognamiglio F, Rodeghiero F, PoglianiEM, Finazzi G, Gugliotta L, Marchioli R,Leone G, Barbui T; GIMEMA CMD-  Recurrent thrombosis in patients withpolycythemia vera and essential thrombocythemia: incidence, risk factors, andeffect of treatments Haematologica. 2008 Mar;93(3):372-80.

Vigna E, Lucia E, Gentile M, Mazzone C, Bisconte MG,Gentile C, Armentano A,  Ottaviani E, Rondoni M, Martinelli G, Morabito F  PDGFRalpha/FIP1L1-positive chroniceosinophilic leukemia presenting with retro-orbital localization: efficacy ofimatinib treatment Cancer Chemother Pharmacol. 2008Apr;61(4):713-6.

Martinelli G, Iacobucci I, Paolini S, Ottaviani E  Farnesyltransferase inhibition inhematologic malignancies: the clinical experience with tipifarnib Clin Adv Hematol Oncol. 2008Apr;6(4):303-10. Review.

Ludwig H, Durie BG, Bolejack V, TuressonI, Kyle RA, Blade J, Fonseca R,Dimopoulos M, Shimizu K, San Miguel J, WestinJ, Harousseau  JL, Beksac M,Boccadoro M, Palumbo A, Barlogie B, Shustik C,Cavo M, Greipp PR, Joshua D, Attal M, Sonneveld P, Crowley J  Myeloma in patients younger than age50 years presents with more favorable features and shows better survival: ananalysis of 10 549  patients from the International Myeloma Working Group Blood. 2008 Apr 15;111(8):4039-47.Epub 2008 Feb 11.

Arpinati M, Chirumbolo G, Rondelli D  Enhancement of T cell activation byimmobilized hu5C8 (anti-CD40L) monoclonal antibody Eur J Haematol. 2008 Apr;80(4):322-30.

Zinzani PL, Tani M, Pulsoni A, Gobbi M, Perotti A, De Luca S, Fabbri A, Zaccaria A, Voso MT, Fattori P, Guardigni L, Ronconi S, Cabras MG, Rigacci L, De Renzo A, Marchi E, Stefoni V, Fina M, Pellegrini C, Musuraca G, Derenzini E, Pileri S, Fanti S, Piccaluga PP, Baccarani M. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxwtan in previously untreted patients with follicular non-Hodgkin  lymphoma trial:a phase II non-randomized trial (FLUMIZ). Lancet Oncol 2008 Apr;9(4):352-8.

Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G,Castellucci P, Marchi E,  Farsad M, Fina M, Pellegrini C, Alinari L,Derenzini E, de Vivo A,  Bacci F,Pileri S, Baccarani M  A phase II trial of CHOP chemotherapyfollowed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previouslyuntreated elderly diffuse large B- cell lymphoma patients Ann Oncol. 2008 Apr;19(4):769-73.

SanMiguel J, Facon T, Cavo M  Recent phase IIItrials in the frontline treatment of multiple myeloma: evaluating theirimpact on community practice Clin Adv Hematol Oncol. 2008Apr;6(4):s4-s10. Review.

Hussein MA, Vrionis FD, Allison R,Berenson J, Berven S, Erdem E, Giralt S,Jagannath S, Kyle RA, LeGrand S,Pflugmacher R, Raje N,  Rajkumar SV, Randall RL,  Roodman D, Siegel D, VescioR, Zonder J, Durie BG; International Myeloma Working  Group  The role of vertebral augmentation inmultiple myeloma: International Myeloma Working Group Consensus Statement Leukemia. 2008 Aug;22(8):1479-84. Epub2008 May 29.

Palumbo A, Bringhen S, Liberati AM, Caravita T, FalconeA, Callea V, Montanaro M, Ria R, Capaldi A, Zambello R, Benevolo G, DerudasD,  Dore F, Cavallo F, Gay F,Falco P, Ciccone G, Musto P, Cavo M, Boccadoro M  Oral melphalan, prednisone, andthalidomide in elderly patients with multiple myeloma: updated results of arandomized, controlled trial Blood. 2008 May 27.

Lorenzini S, Isidori A, Catani L, Gramenzi A, TalaricoS, Bonifazi F, Giudice V, Conte R, Baccarani M, Bernardi M, Forbes SJ, LemoliRM,  Andreone P  Stem cell mobilization and collectionin patients with liver cirrhosis Aliment Pharmacol Ther. 2008May;27(10):932-9.

Follo MY, Finelli C, Mongiorgi S, Clissa C, Bosi C,Martinelli G, Blalock WL,  Cocco L, Martelli AM  PKR is activated in MDS patients andits subcellular localization depends on disease severity Leukemia. 2008 May 22.

Palandri F, Iacobucci I, Castagnetti F, Testoni N,Poerio A, Amabile M,Breccia M, Intermesoli T, Iuliano F, Rege-Cambrin G,Tiribelli M,  Miglino M, Pane F, Saglio G, Martinelli G, Rosti G, Baccarani M;GIMEMA Working Party on CML  Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-yearoutcome Haematologica. 2008 May;93(5):770-4

Medeot M, Zaja F, Vianelli N, Battista M, Baccarani M,Patriarca F, Soldano F,Isola M, De Luca S, Fanin R  Rituximab therapy in adult patientswith relapsed or refractory immune thrombocytopenic purpura: long-termfollow-up results Eur J Haematol. 2008 Sep;81(3):165-9.Epub 2008 May 27

Granito A, Stanzani M, Nuratori L, Bogdanos DP, Muratori P, Pappas G, Quarneti C, Lenzi M, Vergani D, Bianchi FB. LKM1-positive type 2 autoimmune hepatitis following hematopoietic stem-cell transplantation. Am J Gastroenterol 2008 May;103(5):1313-4.

Pfreundschuh M, Ho AD, Cavallin-StahlE, Wolf M, Pettengell R, Vasova I, Belch A, Walewski J, Zinzani PL, MingroneW, Kvaloy S, Shpilberg  O, Jaeger U, Hansen M,Corrado C, Scheliga A, LoefflerM, Kuhnt E; MabThera International Trial (MInT) Group  Prognostic significance of maximumtumour (bulk) diameter in young patients with  good-prognosis diffuselarge-B-cell lymphoma treated  with CHOP-like chemotherapy  with or withoutrituximab: an exploratory analysis of the MabThera International  Trial Group Lancet Oncol. 2008 May;9(5):435-44.

Zaja F, Battista ML, Pirrotta MT, Palmieri S, MontagnaM, Vianelli N, Marin L,Cavallin M, Bocchia M, Defina M, Ippoliti M, FerraraF, Patriarca F, Avanzini MA,Regazzi M, Baccarani M, Isola M, Soldano F, FaninR  Lower dose rituximab is active inadults patients with idiopathic thrombocytopenic purpura Haematologica. 2008 Jun;93(6):930-3.

Vianelli N, Palandri F, Catani L, Boschi L, Poggioli G,Giampalma E,Baccarani M  Partial splenic embolizationpreceding splenectomy, in a case of refractory immune thrombocytopenicpurpura Am J Hematol. 2008 Jun;83(6):520.

Rothenberg ME., Klion AD., Roufosse FE., Kahn JE, Weller PF, Simon HU, Scheartz LB, Resenwasser LJ, Ring J, Griffin EF, Haig AE,  Frewer PI, Parkin JM, Gleich GJ, Mepolizumab HES Study Group. Treatment of patients with the hypereosinophilic syndrome with mepolizumab. N Engl J Med 2008 Jun,5;358(23):2530.

Hochhaus A, Baccarani M, Deininger M,Apperley JF, Lipton JH, Goldberg SL,Corm S, Shah NP, Cervantes F, Silver RT,Niederwieser D,  Stone RM, Dombret H,Larson RA, Roy L, Hughes T, Müller MC,Ezzeddine R, Countouriotis AM, Kantarjian  HM  Dasatinib induces durable cytogeneticresponses in patients with chronic myelogenous leukemia in chronic phase withresistance or  intolerance to imatinib Leukemia. 2008 Jun;22(6):1200-6.

Soverini S, Martinelli G, Iacobucci I, Baccarani M  Imatinib mesylate for the treatmentof chronic myeloid leukemia Expert Rev Anticancer Ther. 2008Jun;8(6):853-64. Review.

Savage KJ, Harris NL, Vose JM, UllrichF, Jaffe ES, Connors JM, Rimsza L,Pileri SA, Chhanabhai M, Gascoyne RD, Armitage JO,  Weisenburger DD; International Peripheral T-Cell Lymphoma Project  ALK- anaplastic large-cell lymphomais clinically and immunophenotypically different from both ALK+ ALCL andperipheral T-cell  lymphoma, not otherwise specified: report from theInternational Peripheral T-Cell Lymphoma Project Blood. 2008 Jun 15;111(12):5496-504.

Fanti S, Castellucci P, Stefoni V, Nanni C, Tani M,Rubello D, Ambrosini V,Zinzani PL, Franchi R  Early relapse in a patient withHodgkin's disease and negative interim FDG-PET Ann Nucl Med. 2008 Jun;22(5):429-32.

Arpinati M, Chirumbolo G, Marzocchi G, Baccarani M,Rondelli D  Increased donor CD86+CD14+ cells inthe bone marrow and peripheral blood of patients with chronicgraft-versus-host disease Transplantation. 2008 Jun27;85(12):1826-32.

Pye SM, Cortes J, Ault P, Hatfield A,Kantarjian H, Pilot R, Rosti G, Apperley JF  The effects of imatinib on pregnancyoutcome Blood. 2008 Jun 15;111(12):5505-8.

Cilloni D, Messa F, Arruga F, Defilippi I, Gottardi E,Fava M, Carturan S,Catalano R, Bracco E, Messa E, Nicoli P, Diverio D, SanzMA,  Martinelli G,Lo-Coco F, Saglio G  Early prediction of treatment outcomein acute myeloid leukemia by measurement of WT1 transcript levels inperipheral blood samples  collected after chemotherapy Haematologica. 2008 Jun;93(6):921-4.

Cilloni D, Messa F, Rosso V, Arruga F, Defilippi I,Carturan S, Catalano R,Pautasso M, Panuzzo C, Nicoli P, Messa E, Morotti A,Iacobucci I,  Martinelli G,Bracco E, Saglio G  Increase sensitivity tochemotherapeutical agents and cytoplasmatic interaction between NPM leukemicmutant and NF-kappaB in AML  carrying NPM1 mutations Leukemia. 2008 Jun;22(6):1234-40.

Lo-Coco F, Cuneo A, Pane F, Cilloni D,Diverio D, Mancini M, Testoni N, Bardi  A, Izzo B, Bolli N, La Starza R, Fazi P, Iacobelli S, Piciocchi A, Vignetti M,Amadori S, Mandelli F, Pelicci PG,Mecucci C, Falini B, Saglio G; Acute Leukemia  Working Party of t  Prognostic impact of geneticcharacterization in the GIMEMA LAM99P multicenter study for newly diagnosedacute myeloid leukemia Haematologica. 2008 Jul;93(7):1017-24.

Piccaluga PP, Califano A, Klein U, Agostinelli C,Bellosillo B, Gimeno E,Serrano S, Solè F, Zang Y, Falini B, Zinzani PL,Pileri SA  Gene expression analysis provides apotential rationale for revising the histological grading of follicularlymphomas Haematologica. 2008 Jul;93(7):1033-8.

Iacobucci I, Lonetti A, Messa F, Cilloni D, Arruga F,Ottaviani E, Paolini S,  Papayannidis C, Piccaluga PP, Giannoulia P, SoveriniS, Amabile  M, Poerio A,Saglio G, Pane F, Berton G, Baruzzi A, Vitale A,Chiaretti S, Perini G, Foa R,Baccarani M, Martinelli G  Expression of spliced oncogenicIkaros isoforms in Philadelphia-positive acute lymphoblastic leukemiapatients treated with tyrosine  kinase inhibitors: implications for a newmechanism of resistance Blood. 2008 Jul 23.

Zuffa E, Mancini M, Brusa G, Pagnotta E, Hattinger CM, Serra M, Remondini D, Castellani G, Corrado P, Barbieri E, Santucci MA.P53 oncosuppressor influences selection of genomic imbalances in response to ionizing radiations in human osteosarcoma cell line  SAOS-2. Int J Radiat Biol 2008 Jul;84(7):591-601.

Pardini S, Fozza C, Contini S, Rimini E, Ottaviani E,Amabile M, Rosti G,Longinotti M  A case of coexistence betweenJAK2V617F and BCR /ABL Eur J Haematol. 2008 Jul;81(1):75-6.

Nanni C, Rubello D, Zamagni E, Castellucci P, AmbrosiniV, Montini G, Cavo M,  Lodi F, Pettinato C, Grassetto G, Franchi R, Gross MD,Fanti  S  18F-FDG PET/CT in myeloma withpresumed solitary plasmocytoma of bone In Vivo. 2008 Jul-Aug;22(4):513-7.

Alessandrino EP, Della Porta MG, Bacigalupo A, Van LintMT, Falda M, Onida F,Bernardi M, Iori AP, Rambaldi A, Cerretti R, Marenco  P,Pioltelli P, Malcovati L,Pascutto C, Oneto R, Fanin R, Bosi A; GruppoItaliano Trapianto di Midollo Osseo  (GITMO) WHO classification and WPSS predictposttransplantation outcome in patients with  myelodysplastic syndrome: astudy from the Gruppo  Italiano Trapianto di Midollo Osseo (GITMO) Blood. 2008 Aug 1;112(3):895-902.

Piccaluga PP, Martinelli G, Isidori A, Malagola M,Rondoni M, Paolini S,Amabile M, Iacobucci I, Baccarani M, Visani G  Long-term molecular completeremission with IFN-alpha in Ph+ adult acute lymphoid leukemia patients Leukemia. 2008 Aug;22(8):1617-8.

Hussein MA, Vrionis FD, Allison R, Berenson J, Berven S, Erdem E, Giralt S, Jagannath S, Kyle RA, LeGrand S, Pflugmacher R, Raje N,  Rajkumar SV, Randall RL, Roodman D, Siegel D, Vescio R, Zonder J, Durie BG; International Myeloma Working Group. The role of vertebral augmentation in multiple myeloma: International Myeloma Working Group Consensus Statement. Leukemia 2008 Aug;22(8):1649.

San Miguel JF, Schlag R, Khuageva NK, Dimopoulos MA, Shpilberg O, Kropff M, Picka I, Petrucci MT, Palumbo A, Samoilova OS,  Dmoszynska A, Abdulkadyrov KM, Schots R, Jiang B, Mateos MV, Anderson KC, Esseltine DL, Liu K, Cakana A, van de Velde H, Richardson  PG;VISTA Trial Investigators. Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma. N Engl J Med 2008 Aug 28;359(9):906-17.

Corrado P, Mancini M, Brusa G, Petta S, Martinelli G,Barbieri E, Santucci MA  Acetylation of FOXO3a transcriptionfactor in response to imatinib of chronic myeloid leukemia Leukemia. 2008 Aug 7.

Agostinelli C, Piccaluga PP, Went P, Rossi M, GazzolaA, Righi S, Sista MT,Campidelli C, Zinzani PL, Falini B, Pileri SA  Peripheral T-cell lymphoma nototherwise-specified: the stuff of genes, dreams and therapies J Clin Pathol. 2008 Aug 28.

San Miguel JF, Schlag R, Khuageva NK,Dimopoulos MA, Shpilberg O, Kropff M,Spicka I, Petrucci MT, Palumbo A,Samoilova OS,  Dmoszynska A, Abdulkadyrov KM,Schots R, Jiang B, Mateos MV,Anderson KC, Esseltine DL, Liu K, Cakana A, van de  Velde H, Richardson  PG;  Bortezomib plus melphalan andprednisone for initial treatment of multiple myeloma N Engl J Med. 2008 Aug28;359(9):906-17.

Tsamita CS, Golemi A, Egesta L, Castellucci P, Nanni C,Stefoni V, Grassetto G, Rubello D, Tani M, Zinzani PL, Fanti S  Clinical significance of axillaryfindings in patients with lymphoma during follow-up with18F-fluorodeoxyglucose-PET Nucl Med Commun. 2008 Aug;29(8):705-10.

Malagola M, Peli A, Damiani D, Candoni A, Tiribelli M,Martinelli G, Piccaluga PP, Paolini S, De Rosa F, Lauria F, Bocchia M, GobbiM, Pierri I,  Zaccaria A,Zuffa E, Mazza P, Priccolo G, Gugliotta L, Bonini A,Visani G, Skert C, Bergonzi  C, Roccaro AM, Filì  Incidence of bacterial and fungalinfections in newly diagnosed acute myeloid leukaemia patients younger than65 yr treated with induction  regimens including fludarabine: retrospectiveanalysis of 224 cases Eur J Haematol. 2008 Aug 19.

Feldman EJ, Cortes J, DeAngelo DJ,Holyoake T, Simonsson B, O'Brien SG,Reiffers J, Turner AR, Roboz GJ, LiptonJH, Maloisel F,  Colombat P, Martinelli G,Nielsen JL, Petersdorf S, Guilhot F,Barker J, Kirschmeier P, Frank E, Statkevich P, Zhu Y, Loechner S, Li  On the use of lonafarnib inmyelodysplastic syndrome and chronic myelomonocytic leukemia Leukemia. 2008Sep;22(9):1707-11.

Falà F, Blalock WL, Tazzari PL, Cappellini A, Chiarini F, Martinelli G, Tafuri A, McCubrey JA, Cocco L, Martelli AM.  Proapoptotic activity and chemosensitizing effect of a noval Akt-inhibitor (2S)-1-(1H-Indol-3-yl)-3-[5-(3-methyl-2H-indazol-5-yl)pyridin-3- yl]oxipropan2-amine(A443654) in T-cell acute lymphoblastic Leukemia. Mol Phrmacol 2008 Sep;74(3):884-95.

Zinzani PL, Martelli M, Poletti V,Vitolo U, Gobbi PG, Chisesi T, Barosi G,Ferreri AJ, Marchetti M, PimpinelliN, Tura S; Italian Society of  Hematology; Italian Society of ExperimentalHematology; Italian Group for Bone Marrow Transplantation  Practice guidelines for themanagement of extranodal non-Hodgkin's lymphomas of adult non-immunodeficientpatients. Part I: primary  lung and mediastinal lymphomas. A project of theItalian Society of Hematology, the Italian Society of Experimental Hematolog Haematologica. 2008Sep;93(9):1364-71.

Patriarca F, Bacigalupo A, Sperotto A, Isola M, Soldano F, Bruno B, van Lint MT, Iori AP, Santarone S, Porretto F, Piolteslli P, Visani G,  Iacopino P, Fanin R, Bosi A; GITMO Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo  Osseo (GITMO). Haematologica 2008 Oct;93(10):1514-22.

Tazzari PL, Tabellini G, Ricci F, Papa V, Bortul R,Chiarini F, Evangelisti C, Martinelli G, Bontadini A, Cocco L, McCubrey JA,Martelli AM  Synergistic proapoptotic activity ofrecombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenousleukemia cells Cancer Res. 2008 Nov 15;68(22):9394-403.

Walz C, Score J, Mix J, Cilloni D,Roche-Lestienne C, Yeh RF, Wiemels JL,Ottaviani E, Erben P, Hochhaus A,Baccarani M, Grimwade D,  Preudhomme C, Apperley J, Martinelli G, Saglio G,Cross NC, Reiter A  The molecular anatomy of theFIP1L1-PDGFRA fusion gene Leukemia. 2008 Nov 6.

Curti A, Trabanelli S, Salvestrini V, Baccarani M,Lemoli RM  The role of indoleamine 2,3-dioxygenasein the induction of immune tolerance: Focus on hematology Blood. 2008 Nov 20.

Dispenzieri A, Kyle R, Merlini G,Miguel JS, Ludwig H, Hajek R, Palumbo A,Jagannath S, Blade J, Lonial S,Dimopoulos M, Comenzo R,  Einsele H, Barlogie B,Anderson K, Gertz M,Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M,Morgan G, RichardsonP, S  International Myeloma Working Groupguidelines for serum-free light chain analysis in multiple myeloma andrelated disorders Leukemia. 2008 Nov 20.

Derenzini E, Musuraca G, Fanti S, Stefoni V, Tani M,Alinari L, Venturini F,  Gandolfi L, Baccarani M, Zinzani PL  Pretransplantation positron emissiontomography scan is the main predictor of autologous stem cell transplantationoutcome in  aggressive B-cell non-Hodgkin lymphoma Cancer. 2008 Nov 1;113(9):2496-503.

Pantaleo MA, Astolfi A, Nannini M, Paterini P, PiazziG, Ercolani G, Brandi G, Martinelli G, Pession A, Pinna AD, Biasco G  Gene expression profiling of livermetastases from colorectal cancer as potential basis for treatment choice Br J Cancer. 2008 Nov 18;99(10):1729-34.

Malagola M., Peli A., Damiani D., Candoni A., Tribelli M., Martinelli G., Piccaluga PP., Paolini S., De Rosa F., Lauria F., Bocchia M., Gobbi M.,  Pierri I., Zaccaria A., Zuffa E., Mazza P., Priccolo G., Gugliotta L., Bonini A., Visani G., Bergonzi C., Roccaro A.M., Filì C., Fanin R., Baccarani  M., Russo D. Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction  regimens including fludarabine:retrospective analysis of 224 cases. Eur J Hematol 2008 Nov,81(5):354-63.

Morschhauser F, Radford J, Van Hoof A, Vitolo U, Souberyan P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez Diaz M, Petrini M,  Sebban C, Zinzani PL, van Oers MH, van Puttern W, Bishof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A. Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in  advanced follicular lymphoma. J Clin Oncol 2008 Nov 10;26(32):5156-64.

Luatti S, Marzocchi G, Ottaviani E, Baldazzi C,Stacchini M, Gamberini C,Salmi F, Martinelli G, Baccarani M, Testoni N  Acute promyelocytic leukemia withamplification of PML-RARalpha rearrangement: Clinical implications Leuk Res. 2008 Dec;32(12):1941-3.

Iacobucci I, Lonetti A, Cilloni D, Messa F, Ferrari A,Zuntini R, Ferrari S,  Ottaviani E, Arruga F, Paolini S, Papayannidis C,Piccaluga PP,  Soverini S,Saglio G, Pane F, Baruzzi A, Vignetti M, Berton G,Vitale A, Chiaretti S, Müschen M, Foà R, Baccarani  Identification of different Ikaros cDNAtranscripts in Philadelphia-positive adult acute lymphoblastic leukemia by ahigh-throughput capillary  electrophoresis sizing method Haematologica. 2008 Dec;93(12):1814-21.

Palandri F, Castagnetti F, Testoni N,Luatti S, Marzocchi G, Bassi S, Breccia M, Alimena G, Pungolino E,Rege-Cambrin G, Varaldo R,  Miglino M, Specchia G,Zuffa E, Ferrara F, BocchiaM, Saglio G, Pane F, Alberti D, Martinelli G,Baccarani M, Rosti G; GIMEM  Chronic myeloid leukemia in blast crisistreated with imatinib 600 mg: outcome of the patients alive after a 6-yearfollow-up Haematologica. 2008Dec;93(12):1792-6.

Latagliata R, Breccia M, Fazi P, Iacobelli S,Martinelli G, Di Raimondo F,Sborgia M, Fabbiano F, Pirrotta MT, Zaccaria A,Amadori S, Caramatti  C, Falzetti  F, Candoni A, Mattei D, Morselli M, AlimenaG, Vignetti M, Baccarani M, Mandelli  F  Liposomal daunorubicin versus standarddaunorubicin: long term follow-up of the GIMEMA GSI 103 AMLE randomized trialin patients older  than 60 years with acute myelogenous leukaemia Br J Haematol. 2008 Dec;143(5):681-9.

Martinelli G, Soverini S, Iacobucci I, Baccarani M  Intermittent targeting as a tool tominimize toxicity of tyrosine kinase inhibitor therapy Nat Clin Pract Oncol. 2008 Dec 17.Pagano L, Valentini CG, Caira M, Rondoni M, Van Lint MT, Candoni A, Allione B, Cattaneo C, Marbello L, Caramazzi C, Pogliani EM, Iannitto  E, Giona F, Ferrara F, Invernizzi R, Fanci R, Lunghi M, Fianchi L, Sanpaolo G, Stefani PM, Pulsoni A, Martinelli G, Leone G, Musto P. Advanced mastcell disease: an Italian Hematological Multicenter Experience. Int J Hematol 2008 Dec;88(5):483-8.

Pagano L, Valentini CG, Caira M, Rondoni M, Van LintMT, Candoni A, Allione B,Cattaneo C, Marbello L, Caramatti C, Pogliani EM,Iannitto E,  Giona F, Ferrara F,Invernizzi R, Fanci R, Lunghi M, Fianchi L,Sanpaolo G, Stefani PM, Pulsoni A,Martinelli G, Leon  Advanced mast cell disease: an Italian Hematological Multicenter experience Int J Hematol. 2008 Dec;88(5):483-8.

Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A, Iriondo A, Cook G, Pettitt A, Socie G, Bonifazi F, Bosi A, Michallet  M, Liakopoulou E, Maertens J, Passweg J, Clarke F, Martino R, Schmitz N; on behalf of the Lymphoma Working Party of the EBMT. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin's lymphoma: identification of prognostic factors predicting  outcome. Haematologica 2008 Dec 9.

Tosi P, Barosi G, Lazzaro C, Liso V, Marchetti M, MorraE, Pession A, Rosti G,Santoro A, Zinzani PL, Tura S  Consensus conference on the managementof tumor lysis syndrome Haematologica. 2008 Dec;93(12):1877-85.

Cavo M, Attal M, Gertz MA, Giralt S, Ludwig H, MorganGJ, Anderson KC  The current landscape of multiplemyeloma treatment Leuk Res. 2008 Dec;32 Suppl 1:S1-24.

Candoni A, Martinelli G, Toffoletti E, Chiarvesio A,Tiribelli M, Malagola M,  Piccaluga PP, Michelutti A, Simeone E, Damiani D,Russo D,  Fanin R  Gemtuzumab-ozogamicin in combinationwith fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy inCD33-positive AML  patients younger than 65 years Leuk Res. 2008 Dec;32(12):1800-8.

Follo MY, Finelli C, Clissa C, Mongiorgi S, Bosi C,Martinelli G, Baccarani M,Manzoli L, Martelli AM, Cocco L  Phosphoinositide-Phospholipase C {beta}1 Mono-AllelicDeletion Is Associated With Myelodysplastic Syndromes Evolution Into  AcuteMyeloid Leukemia J Clin Oncol.



 
Istituto di Ematologia "Lorenzo e Ariosto Seràgnoli" - Via Massarenti, 9 - 40138 Bologna - Tel. +39 051 636 3680 Fax +39 051 636 4037